{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-005707","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.378346+00:00","generated_at":"2026-06-05T14:08:31.327376+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO Health Q4 revenue $181.9M; net loss narrows to $0.09/sh; $230M convertible notes issued","bullets":["Consolidated revenue $181.9M vs $185.4M in prior-year quarter; net loss $65.5M ($0.09/sh) vs $85.2M ($0.11/sh).","Diagnostics segment revenue fell 11% to $124.2M on lower reimbursement and COVID-19 testing decline.","Pharmaceuticals revenue rose to $43.0M, driven by international operations and RAYALDEE sales of $9.3M.","After quarter end, OPKO sold $230M of 3.75% convertible senior notes due 2029 and used $50M to repurchase stock.","BioReference Health REACH program reduced annualized expenses by $10.1M; operating loss $42.3M including $4.7M non-recurring."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-005707","json":"https://secwatch.observer/filing/0001437749-24-005707.json","markdown":"https://secwatch.observer/filing/0001437749-24-005707.md","text":"https://secwatch.observer/filing/0001437749-24-005707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/0001437749-24-005707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/opk20240226_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T14:08:31.327376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"084becad7fa7b4b470e4557826eda17a306b57a5","claim":"OPKO HEALTH, INC. reported three and 12 months ended December 31, 2023 results: revenue $181.9 million, net income Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share, EPS $0.09 per share.","evidence_excerpt":"of revenue adjustments, compared with an operating loss of $23.1 million in the 2022 period. ● Consolidated: Consolidated total revenues for the fourth quarter of 2023 were $181.9 million compared with $185.4 million for the comparable 2022 period. Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/0001437749-24-005707-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and 12 months ended December 31, 2023"},{"label":"Revenue","value":"$181.9 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2023 was $65.5 million, or $0.09 per share"},{"label":"EPS","value":"$0.09 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}